Literature DB >> 11252027

Member of the Ampakine class of memory enhancers prolongs the single channel open time of reconstituted AMPA receptors.

V Suppiramaniam1, B A Bahr, S Sinnarajah, K Owens, G Rogers, S Yilma, V Vodyanoy.   

Abstract

Ampakines are small benzamide compounds that allosterically produce the positive modulation of AMPA receptors and improve performance on a variety of behavioral tasks. To test if the native synaptic membrane is necessary for the effects of such positive modulators, the mechanism of action of the Ampakine 1-(1,3-benzodioxol-5-ylcarbonyl)-1,2,3,6-tetrahydropyridine (CX509) was investigated in isolated rat brain AMPA receptors reconstituted in lipid bilayers. The drug increased the open time of AMPA-induced single channel current fluctuations with an EC(50) of 4 microM. The action of CX509 was highly selective since it had no effect on the amplitude or close time of channel events. The open time effect had a maximum enhancement of 70-fold and the modulated currents were blocked by CNQX. It is concluded that the synaptic membrane environment is not necessary for Ampakine effects. In fact, CX509 was about 100 times more potent on the reconstituted AMPA receptors than on receptors in their native membrane. These findings indicate that centrally active Ampakines modulate specific kinetic properties of AMPA currents. They also raise the possibility that AMPA receptors are regulated by factors present in situ, thus explaining the more efficient modulatory effects of CX509 when acting on receptors removed from their synaptic location. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11252027     DOI: 10.1002/syn.1037

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  11 in total

Review 1.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

2.  AMPAKINE enhancement of social interaction in the BTBR mouse model of autism.

Authors:  J L Silverman; C F Oliver; M N Karras; P T Gastrell; J N Crawley
Journal:  Neuropharmacology       Date:  2012-07-16       Impact factor: 5.250

3.  Ampakine CX717 potentiates intermittent hypoxia-induced hypoglossal long-term facilitation.

Authors:  S M Turner; M K ElMallah; A K Hoyt; J J Greer; D D Fuller
Journal:  J Neurophysiol       Date:  2016-06-15       Impact factor: 2.714

4.  Structural and functional analysis of two new positive allosteric modulators of GluA2 desensitization and deactivation.

Authors:  David E Timm; Morris Benveniste; Autumn M Weeks; Eric S Nisenbaum; Kathryn M Partin
Journal:  Mol Pharmacol       Date:  2011-05-04       Impact factor: 4.436

Review 5.  Therapeutic acute intermittent hypoxia: A translational roadmap for spinal cord injury and neuromuscular disease.

Authors:  Alicia K Vose; Joseph F Welch; Jayakrishnan Nair; Erica A Dale; Emily J Fox; Gillian D Muir; Randy D Trumbower; Gordon S Mitchell
Journal:  Exp Neurol       Date:  2021-10-09       Impact factor: 5.330

6.  Mechanisms underlying cognitive enhancement and reversal of cognitive deficits in nonhuman primates by the ampakine CX717.

Authors:  R E Hampson; R A España; G A Rogers; L J Porrino; S A Deadwyler
Journal:  Psychopharmacology (Berl)       Date:  2008-11-05       Impact factor: 4.530

7.  Mifepristone prevents stress-induced apoptosis in newborn neurons and increases AMPA receptor expression in the dentate gyrus of C57/BL6 mice.

Authors:  María Llorens-Martín; José L Trejo
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

8.  Neuroimaging of Supraventricular Frontal White Matter in Children with Familial Attention-Deficit Hyperactivity Disorder and Attention-Deficit Hyperactivity Disorder Due to Prenatal Alcohol Exposure.

Authors:  Jeffry R Alger; Joseph O'Neill; Mary J O'Connor; Guldamla Kalender; Ronald Ly; Andrea Ng; Andrea Dillon; Katherine L Narr; Sandra K Loo; Jennifer G Levitt
Journal:  Neurotox Res       Date:  2021-03-22       Impact factor: 3.978

Review 9.  Molecular targets for treating cognitive dysfunction in schizophrenia.

Authors:  John A Gray; Bryan L Roth
Journal:  Schizophr Bull       Date:  2007-07-07       Impact factor: 7.348

10.  Facilitation of task performance and removal of the effects of sleep deprivation by an ampakine (CX717) in nonhuman primates.

Authors:  Linda J Porrino; James B Daunais; Gary A Rogers; Robert E Hampson; Sam A Deadwyler
Journal:  PLoS Biol       Date:  2005-08-23       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.